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ABSTRACT
Objective: The aim of the present study was to evaluate parameters of bone and mineral metabolism 
after bariatric surgery. Subjects and methods: This sectional study included data from medical 
records from 61 bariatric surgery (BS) patients (minimum period of 6 months after the procedure) 
and from 30 class II and III obese patients as a control group (Cont), consisting of daily dietary intake 
of macronutrients, calcium and sodium, serum 25(OH)D and parathyroid hormone (PTH) and other 
biochemical serum and urinary parameters. Bone alkaline phosphatase (BAP), leptin, fibroblast 
growth factor-23 (FGF-23) and deoxypyridinoline (DPYD) were determined from available banked 
serum and urinary samples. Results: Mean body mass index (BMI), median energy, carbohydrate, 
protein and sodium chloride consumption were significantly lower in the BS versus Cont, but calcium 
and lipids were not. No significant differences were found in ionized calcium, 25(OH)D, PTH and 
fibroblast growth factor 23 (FGF-23) between groups. Mean serum BAP was significantly higher for 
BS versus Cont and had a positive correlation with time after the surgical procedure. Mean serum 
leptin was significantly lower and median urinary DPYD higher in BS versus Cont. Conclusion: The 
present study showed an increase in bone markers of both bone formation and resorption among 
bariatric patients up to more than 7 years after the surgical procedure, suggesting that an increased 
bone turnover persists even at a very long-term follow-up in such patients. Arch Endocrinol Metab. 
2017;61(3):332-6.
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INTRODUCTION
T he prevalence of obesity has increased during the past decades representing a major public 
health problem. A high body mass index (BMI) has 
been directly associated with higher bone mineral 
density (BMD) given that mechanical loading under 
physiological conditions possesses a central role on bone 
mass maintenance. Therefore, it has been well accepted 
until recently, that obesity was associated with a reduced 
risk of osteoporosis and that fat mass had a similar 
beneficial effect on increasing bone mass (1). However, 
contrasting studies now show that excessive fat mass 
may not protect against osteoporosis (2) and that lean 
mass may be a more important determinant of BMD 
(3). Moreover, adipose tissue expresses and secretes 
several biologically active hormones and cytokines such 
as estrogen, leptin, among others, which may affect 
energy homeostasis and bone metabolism (4).
Bariatric surgery (BS) is an effective treatment for 
clinically severe obesity and Roux-en-Y gastric bypass, 
the most common technique, induces an important 
and sustained weight loss improving comorbidities. 
However, the procedure entails long-term complications 
such as nutritional deficiencies, nephrolithiasis (5), 
as well as other disturbances in bone and mineral 
metabolism, including low bone mass and increased 
risk of fractures after a substantial weight loss (6-9). 
Bone loss may be attributed to a reduction of lean body 
mass during the weight reduction process, previous 
obesity-induced hypovitaminosis D, which persists 
even after surgery, and malabsorption of calcium and 
vitamin D following the procedure (10,11). De Prisco 
and Levine (6) reported osteomalacia and osteoporosis 
among bariatric patients up to 12 years after procedure, 
suggesting that this population is at risk for metabolic 
bone disease at a long-term basis. 
Previous studies that evaluated skeletal changes 
after bariatric surgery through dual-energy x-ray 
absorptiometry (DXA), quantitative computed 
tomography (QCT) and high-resolution peripheral 
computed tomography (HR-pQCT) demonstrated 
a decreased BMD and also increased bone turnover 
markers (7,9,12-15).
Therefore, bone loss is a multifactorial complication 
in bariatric patients although the underlying 
mechanisms are not fully elucidated. The aim of the 
present study was to evaluate parameters of bone and 
mineral metabolism after bariatric surgery.
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SUBJECTS AND METHODS
A sectional study was carried out by the review of 80 
medical records from class II and III obese patients 
who had undergone bariatric surgery (BS) through 
Roux-en-Y (RYGB) or biliopancreatic diversion with 
duodenal switch (BD-DS) between 2007 and 2010 at 
the Universidade Federal de São Paulo. Eligible patients 
for inclusion were those with a minimum period of 6 
months post-surgery, who had dietary information 
obtained through 72 hour food recalls, as well as 
results from serum levels of 25(OH)D and parathyroid 
hormone (PTH), and other biochemical serum and 
urinary (retrieved from 24 hour urine specimens) 
parameters under conditions of discontinuation of 
multi-vitamins and/or calcium supplementation 72 
hours before collection. Serum biochemistry comprised 
values of creatinine, albumin and ionized calcium and 
urinary parameters included calcium, sodium and 
creatinine. This retrospective analysis was followed by 
a further selection of patients whose banked serum 
and urine samples were available for the determination 
of additional mineral metabolism parameters, such 
as fibroblast grow factor-23 (FGF-23), bone alkaline 
phosphatase (BAP), deoxypyridinoline (DPYD) as well 
as leptin. Exclusion criteria were age < 18 years old, 
abnormal renal function (estimated glomerular filtration 
rate (eGFR) by CKD-EPI creatinine equation < 60 mL/
min/1.73 m2) and history of medical disorders known 
to affect bone metabolism (e.g., hyperthyroidism, 
hyperparathyroidism, renal disease, Paget’s disease, etc.). 
The study was approved by the local Ethics 
Committee of the Institution and a written consent 
was obtained from all participants. The control group 
(Cont) consisted of data from age-matched obese 
patients with a body mass index [BMI] 35.0–39.9 
(obesity class II) and ≥ 40 kg/m2 (obesity class III) 
waiting for bariatric surgery, whose similar parameters 
could be used for comparisons.
Serum BAP (Quidel, San Diego, CA), FGF-23 
(Kainos Laboratories, Tokyo, Japan), fasting serum leptin 
(Merck Millipore, Darmstadt, Alemanha) and urinary 
DPYD (MicroVue DPD EIA, Quidel Corporation, San 
Diego, USA) were measured by ELISA.
Statistical analyses
It was estimated that this sample size would provide 
95% of power, at a significance level of 0.01, to detect 
changes in primary endpoints by including at least 
15 patients in each group. The software G. Power 
3.1.2 was used for the sample calculation (Franz Faul, 
University of Kiel, Germany). 
Normally distributed variables are presented as mean 
± standard deviation and skewed variables as median 
[interquartile interval]. Differences between groups 
were assessed using T tests or Mann Whitney when 
appropriated. Categorical comparisons were assessed 
using x2-square test. Spearman’s correlation as used 
to examine the relationship between change in serum 
markers of bone turnover and time after procedure. 
All statistical analyses were performed using SPSS 
(Statistical Package Social Sciences) software version 18 
for Windows (Illinois, MA, USA). A p value ≤ 0.05 was 
considered statistically significant.
RESULTS
After exclusion of missing data on nutritional 
assessment, biochemical and hormonal parameters, 
61 BS (n = 58 RYGB and n = 3 BD-DS) and 30 
Cont were available for enrollment in the study. The 
median [IQR] post-surgical time was 4 [1-7] years 
and the mean decrease in BMI after surgery was 36% 
(data not shown in table). As shown in Table 1, no 
significant differences were observed regarding gender 
distribution and mean age between BS and Cont. The 
mean values of BMI, daily dietary intake of energy, 
carbohydrate, protein and sodium chloride (estimated 
from 24-hour urinary sodium, for better accuracy) 
were significantly lower in the BS compared to Cont. 
Daily consumption of calcium and lipids did not differ 
between groups. The mean serum BAP was significantly 
higher for BS versus Cont patients and had a positive 
correlation with time after procedure (r = 0,278, p = 
0,04). Serum leptin was lower in BS group compared 
to Cont and no significant differences were found in 
eGFR, ionized calcium, albumin, 25(OH)D, PTH and 
FGF-23 between groups. Urinary DPYD was higher, 
calcium and sodium were lower in BS versus Cont.
DISCUSSION
The main finding of the present study was an increased 
bone turnover, disclosed among bariatric patients in the 
late postoperative period when compared to morbidly 
obese individuals. 
Several investigators have reported bone mineral 
metabolism disturbances following bariatric surgery, 
including either reduced BMD (8,11-13) or alterations 
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in bone biochemical markers of bone turnover 
(14,15). Although hypovitaminosis D, secondary 
hyperparathyroidism and mechanical unloading of the 
skeleton due to weight loss have been implicated, the 
underlying mechanisms responsible for such changes 
are not fully elucidated. 
In the present study, median serum 25(OH)D in 
BS group was low and not different from Cont before 
surgery, which agrees well with other reports (9,12). 
Whereas hypovitaminosis D in class II and III obese 
patients more often occurs because of the sequestration 
of vitamin D in adipose tissue (16), the reasons in BS 
patients include not only pre-operative low levels of 
25(OH)D (15), but also low compliance with oral 
supplements (17). In the current series, despite of the 
low calcium consumption besides hypovitaminosis 
D, BS group did not present a higher median serum 
PTH. Nevertheless, the presence of secondary 
hyperparathyroidism among bariatric patients is still 
a matter of debate since some investigators reported 
normal levels of PTH (8,13,15), while others did not 
(14,18,19). 
The significantly higher serum BAP levels in BS 
than Cont patients observed in the present study 
suggests the presence of increased bone formation, 
in agreement with the data reported by Bruno and 
cols. (15) and with other investigators, who employed 
different biochemical markers of bone formation 
(8,12). Moreover, urinary DPYD was also higher in 
BS patients than in Cont, indicating an increased bone 
resorption, as detected by other investigators (20,21), 
even when using different bone resorption markers 
as well (8,20,22,23). Therefore, an increased bone 
turnover has been clearly evidenced by the present 
findings, which corroborates with numerous reports 
(8,12,13,15,24), although not with all of them (9,21).
We observed a low calcium intake by BS patients 
(similarly to Cont), as observed by Menegati and cols. 
(19), what may be a caution against dumping (25). 
Inadequate calcium intake may contribute to impair 
bone homeostasis, due to increases in serum PTH and 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (26), and a 
high sodium consumption may also compromises bone 
health (27,28). Furthermore, the presence of reduced 
Table 1. Nutritional data, serum and urinary parameters
Parameter Cont [n = 30] BS [n = 61] p
Gender (F/M) 23/7 51/9 0.52
Age (years) 48.0 ± 8.8 47.1 ± 9.9 0.69
eGFR 102 [85-111] 104 [97-109] 0.32
BMI [kg/m²] 46.5 ± 7.3 31.5 ± 6.0 < 0.001
Energy [kcal] 1739 [1182-2743] 1272 [931-1714] 0.01
Dietary carbohydrate [g] 199 [149-390] 142 [106-192] < 0.001
Dietary protein [g] 75 [62-100] 51 [39-70] < 0.001
Dietary lipids [g] 45 [27-57] 53 [32-76] 0.27
Dietary calcium [mg] 502 [395-1278] 517 [324-740] 0.32
Dietary NaCl [g] 11 [7-15] 8 [6-11] 0.01
Serum ionized Calcium [mmol/L] 1.3 ± 0.0 1.3 ± 0.0 0.15
Serum Albumin [g/dL] 4.2 ± 0.2 4.2 ± 0.2 0.80
Serum 25(OH)D [ng/mL] 21.0 [17-24] 19.1 [14-26] 0.51
Serum PTH [pg/mL] 61.0 ± 22.7 61.0 ± 23.8 0.98
Serum FGF-23 [kRU/mL] 41.1 [27-53] 44.4 [16-58] 0.53
Serum BAP [U/L] 17.9 ± 5.6 24.2 ± 9.6 0.003
Serum Leptin [ng/mL] 44.7 ± 11.6 32.2 ± 14.6 < 0.001
Urinary DPYD [nmol/mmol creat] 5.1 [3-6] 5.6 [3-9] 0.041
Urinary calcium [mg/24h] 161 [23-488] 89 [21-270] 0.001
Urinary sodium [mg/24h] 184 [122-252] 141 [105-181] 0.01
Urinary creatinine [mg/24h] 1474 ± 511 1112 ± 302 0.000
Data are presented as mean ± SD or median [interquartile interval]. Cont: control group, BS: bariatric surgery, eGFR: estimated glomerular filtration rate, BMI: body mass index, PTH: parathyroid 
hormone, FGF-23: fibroblast growth factor-23, BAP: bone alkaline phosphatase, DPYD: deoxypyridinoline.
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intestinal calcium absorption even under conditions 
of both calcium and vitamin D supplementation in 
bariatric patients (11) may render bone condition even 
worse. The observed increased bone turnover in BS 
group could be accounted for by a negative calcium 
balance. However, given that urinary calcium and 
sodium were significantly lower in BS versus Cont, the 
contribution of negative calcium balance did not seem 
to be important. 
The present sample consisted of bariatric patients with 
a median follow-up of 4 years after the procedure with a 
handful of them attaining more than 7 years of follow-
up. Of note, we found a positive correlation of serum 
BAP with time after surgery. A substantial increase in 
bone formation and resorption markers had occurred up 
to 24 months after gastric bypass despite weight stability, 
as described by many authors (12,13,29), reinforcing 
that bone remodeling remains elevated despite weight 
loss plateaus after the first year and are not exclusively 
due to mechanical unloading of the skeleton.
It is well recognized that the adipose tissue 
synthesizes and releases a series of hormones and 
adipokines involved in bone metabolism through 
direct effects on bone formation and resorption (30). 
When compared to Cont, bariatric patients from the 
current series presented a lower mean value of serum 
leptin, one of the most important cytokines derived 
from fat tissue, which acts on hypothalamic neurons 
by stimulating sympathetic postganglionic neurons via 
axons that enter the bones to inhibit bone formation 
(31,32). Our findings are in agreement with other 
reports after bariatric surgery (13,15). Bruno and cols. 
(15) also showed that a reduction in leptin represented 
an independent predictor of increase in N-teloptide 
of type 1 collagen (NTX), a bone resorption 
marker, among bariatric patients. A more recent 
study of bone structural changes evaluated through 
high-resolution peripheral quantitative computed 
tomography by Frederiksen and cols. (13) revealed 
an inverse association between leptin and trabecular 
number. Although there is still some controversy 
regarding the correlation of leptin with BMD (30), 
Thomas and cols. (33) noticed a direct association 
between leptin and BMD only among women, in 
the general population, suggesting that leptin could 
mediate at least part of the protective effect of fat 
mass on the skeleton. However, the reciprocal action 
between bone and adipose tissue is complex and the 
underlying mechanisms by which leptin regulates bone 
remodeling remain not fully elucidated (34). In an 
experimental study, Tsuji and cols. (35) showed that 
leptin increased FGF-23 expression in leptin-deficient 
ob/ob mice, acting directly on bone cells, and 
suppressed renal 1,25(OH)2D3 synthesis. Conversely, 
one may speculate that the reduction of leptin 
following bariatric surgery could be associated with 
an increased 1,25(OH)2D3, hence contributing to 
stimulate bone resorption, especially under conditions 
of low calcium consumption (26). However, in the 
current series, median values of serum FGF-23 did not 
differ between groups, even in the presence of lower 
serum leptin in BS versus Cont. Moreover, levels of 
1,25(OH)2D3 were not determined. Other limitations 
of the present study included the lack of BMD and 
body composition data from both groups and the 
absence of enough test results of mineral metabolism 
parameters among bariatric patients before the surgery, 
to allow us to make comparisons before and after the 
procedure.
In summary, BS patients exhibited significantly 
higher serum BAP, urinary DYPD and lower serum 
leptin levels than Cont, without statistical significance 
in circulating levels of 25(OH)D and PTH, indicating 
that other mechanisms, not solely associated to the 
calciotropic hormones, might be operating to explain 
the increased bone turnover after bariatric surgery. 
Such findings are in agreement with other investigators 
(14,18) and according to Bruno and cols. (15), even 
the supplementation of vitamin D was not capable 
to prevent the increase in bone turnover seen after 
bariatric surgery.
In conclusion, the present study showed an 
increase in bone markers of both bone formation and 
resorption among bariatric patients up to more than 7 
years after the surgical procedure, suggesting that an 
increased bone turnover persists even at a very long-
term follow-up in such patients. Additional studies 
are still warranted to better elucidate the underlying 
mechanisms for these findings, aiming to mitigate 
derangements in bone metabolism and helping to 
delineate earlier interventions.
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